U.S. Markets close in 1 hr 56 mins
  • S&P 500

    4,136.35
    +8.36 (+0.20%)
     
  • Dow 30

    33,632.06
    -113.34 (-0.34%)
     
  • Nasdaq

    13,951.58
    +101.58 (+0.73%)
     
  • Russell 2000

    2,215.93
    -17.85 (-0.80%)
     
  • Crude Oil

    60.10
    +0.40 (+0.67%)
     
  • Gold

    1,746.10
    +13.40 (+0.77%)
     
  • Silver

    25.39
    +0.52 (+2.10%)
     
  • EUR/USD

    1.1946
    +0.0028 (+0.2389%)
     
  • 10-Yr Bond

    1.6250
    -0.0500 (-2.99%)
     
  • Vix

    16.68
    -0.23 (-1.36%)
     
  • GBP/USD

    1.3745
    +0.0002 (+0.0179%)
     
  • USD/JPY

    109.1010
    -0.2750 (-0.2514%)
     
  • BTC-USD

    63,437.62
    +3,529.14 (+5.89%)
     
  • CMC Crypto 200

    1,359.62
    +65.63 (+5.07%)
     
  • FTSE 100

    6,890.49
    +1.37 (+0.02%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
Autolus Limited
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021. The company will also host one-on-one meetings with attendees.

A live audio webcast of the presentation will be available on-demand on the investor relations section of Autolus’ website at events starting March 9 at 7.00 a.m. EST. An archived replay will be available on the company’s website for a period of 90 days after the conference.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com